One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort StudyÂ
Sung Noh Hong, MD, PhD, Joo Hye Song, MD, PhD, Sung Jin Kim, MS, Yoon Ha Park, RN, Chang Wan Choi, MD, Ji Eun Kim, MD, PhD, Eun Ran Kim, MD, PhD, Dong Kyung Chang, MD, PhD, Young-Ho Kim, MD, PhD
doi : 10.1093/ibd/izad094
Volume 30, Issue 4, April 2024
Characterization of the Gut Microbiota and Mycobiota in Italian Pediatric Patients With Primary Sclerosing Cholangitis and Ulcerative ColitisÂ
Federica Del Chierico, MS, Sabrina Cardile, MD, Valerio Baldelli, PhD, Tommaso Alterio, MD, Sofia Reddel, MS, Matteo Bramuzzo, MD, Daniela Knafelz, MD, Sara Lega, MD, Fiammetta Bracci, MD, Giuliano Torre, MD, Giuseppe Maggiore, MD, PhD, Lorenza Putignani, PhD
doi : 10.1093/ibd/izad203
Impact of Inflammatory Bowel Disease on Patients’ Caregivers: Results From a French Survey
Weam El Hajj, MD, Anne Buisson, MD, Alain Olympie, MD, Marie Hélène Ravel, MD, Corinne Devos, MD, Caroline Trang-Poisson, MD, Gilles Macaigne, MD, Stéphane Nahon, MD
doi : 10.1093/ibd/izad093
Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn’s Disease
Tanita Suttichaimongkol, MD, Edward V Loftus, Jr., MD
doi : 10.1093/ibd/izad104
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
Sruthi Adimadhyam, PhD, James D Lewis, MD, MSCE, Andrew L Simon, ScM, Audrey E Wolfe, MPH, Samantha Smith, BA, Laura Hou, MS, Érick Moyneur, MA, Juliane S Reynolds, MPH, Sengwee Toh, ScD, Angela Dobes, MPH, Lauren Parlett, PhD, Kevin Haynes, PharmD, MSCE, Jessica Burris, MD, Jennifer E Dorand, PhD, Millie D Long, MD, MPH, Michael D Kappelman, MD, MPH
doi : 10.1093/ibd/izad115
Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Mohammad Shehab, MD, MRCP (United Kingdom), ABIM, FRCPC, Sahad Al Akram, MD, Amro Hassan, MD, Fatema Alrashed, MPharm, MSc, PharmD, BCPS, Vipul Jairath, MBChB, DPhil, Talat Bessissow, MDCM, MSc, FRCPC
doi : 10.1093/ibd/izad119
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-AnalysisÂ
Daniele Piovani, MSc, PhD, Alessandro Armuzzi, MD, PhD, Stefanos Bonovas, MD, MSc, PhD
doi : 10.1093/ibd/izad109
Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis
Vikas Taneja, MD, Rajsavi S Anand, MD, Mohammed El-Dallal, MD, Jeffrey Dong, MD, Nisa Desai, MD, Isha Taneja, MPH, Joseph D Feuerstein, MD
doi : 10.1093/ibd/izad108
Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not
Priya Sehgal, MD, MPH, Steven Su, MD, PhD, John Zech, MD, Yael Nobel, MD, MS, Lyndon Luk, MD, Ioannis Economou, MD, Bo Shen, MD, James D Lewis, MD, Daniel E Freedberg, MD, MS
doi : 10.1093/ibd/izad111
Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease: A Prospective, Comparative Study
Angela Mujukian, MD, Rashmi Kumar, MD, Dalin Li, PhD, Philip Debbas, Gregory J Botwin, Susan Cheng, MD, PhD, Joseph Ebinger, MD, Jonathan Braun, MD, PhD, Dermot McGovern, MD, PhD, Gil Y Melmed, MD, MS, The CORALE-IBD Study Group
doi : 10.1093/ibd/izad114
Revisiting the Role of Valeric Acid in Manipulating Ulcerative Colitis
Moting Liu, MSc, Yao Zhang, BSc, Jia Liu, PhD, Caigui Xiang, PhD, Qiukai Lu, MSc, Huimin Lu, PhD, Tao Yang, BSc, Xiaohan Wang, MSc, Qingli Zhang, MSc, Chen Fan, MSc, Chunlan Feng, BSc, Duowu Zou, PhD, MD, Heng Li, PhD, Wei Tang, PhD, MD
doi : 10.1093/ibd/izad187
Unveiling the Ghrelin and Obestatin Roles in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Assessing Their Pathogenic Implications and Biomarker Utility
Amirmohammad Khalaji, MD, Nastaran Babajani, MD, Zahra Amirsardari, MD, Behrad Saeedian, MD, Soheil Peiman, MD, Nathan A Berger, MD, Amir Hossein Behnoush, MD, MPH
doi : 10.1093/ibd/izad202
Exclusive Enteral Nutrition Mediates Beneficial Gut Microbiome Enrichment in Acute Severe Colitis
Aditya Bajaj, MSc, Manasvini Markandey, MSc, Mukesh Singh, PhD, Pabitra Sahu, MD, DM, Sudheer K Vuyyuru, MD, DM, Bhaskar Kante, MD, DM, Peeyush Kumar, MD, DM, Mahak Verma, MSc, Govind Makharia, MD, DM, Saurabh Kedia, MD, DM, Simon P L Travis, DPhil, Vineet Ahuja, MD, DM
doi : 10.1093/ibd/izad232
Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis
Sudheer K Vuyyuru, MD, Tran M Nguyen, MSc, Malcolm Hogan, MSc, Tim Raine, MD, Nurulamin M Noor, MD, Neeraj Narula, MD, Bram Verstockt, MD, Brian G Feagan, MD, Siddharth Singh, MD, Christopher Ma, MD, Vipul Jairath, MBChB, Dphil
doi : 10.1093/ibd/izad052
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel DiseaseÂ
Abhinav Vasudevan, MD, Vivek Tharayil, MD, Laura H Raffals, MD, David H Bruining, MD, Michelle Becker, PharmD, Mohammad Hassan Murad, MD, Edward V Loftus, Jr., MD
doi : 10.1093/ibd/izad065
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease
Nuria Tubau-Juni, PhD, Raquel Hontecillas, PhD, DVM, Andrew J Leber, PhD, Sameeksha S Alva, MS, Josep Bassaganya-Riera, PhD, DVM
doi : 10.1093/ibd/izad258
Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis
Christian Karime, MD, Francis A Farraye, MD, MSc, Jana G Hashash, MD, MSc
doi : 10.1093/ibd/izad098
Long-term Efficacy and Safety of Tacrolimus Plus Ustekinumab Combination Therapy in Children With Steroid-refractory Ulcerative ColitisÂ
Ryusuke Nambu, MD, Ayako Miyazawa, MD, Masashi Yoshida, MD, Tomoko Hara, MD, Itaru Iwama, MD
doi : 10.1093/ibd/izae013
Revisiting the Risk of Hospital Readmission in Severe Ulcerative Colitis
Yusuke Miyatani, MD, Dejan Micic, MD
doi : 10.1093/ibd/izad212
Surgical Complications Need to Be Carefully Excluded Before Ruling Out a Diagnosis of De Novo Crohn’s Disease
Massimo Martinelli, MD, PhD, Erasmo Miele, MD, PhD, Annamaria Staiano, MD
doi : 10.1093/ibd/izae026
Response to “De Novo Crohn’s Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN�
Djuna de Jong, MD, MSc, Maud Reijntjes, MD, PhD, Christianne Buskens, MD, PhD, Roel Hompes, MD, PhD, Geert D’Haens, MD, PhD, Willem Bemelman, MD, PhD, Marjolijn Duijvestein, MD, PhD
doi : 10.1093/ibd/izae021
Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance
Sem Geertsema, MD, Raphael R Fagundes, PhD, Antonius T Otten, MD, Gerard Dijkstra, MD, PhD, Klaas Nico Faber, PhD, Arno R Bourgonje, MD, PhD
doi : 10.1093/ibd/izae042
Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance
Keiko Maeda, MD, PhD, Hiroki Kawashima, MD, PhD
doi : 10.1093/ibd/izae039
One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort StudyÂ
Sung Noh Hong, MD, PhD, Joo Hye Song, MD, PhD, Sung Jin Kim, MS, Yoon Ha Park, RN, Chang Wan Choi, MD, Ji Eun Kim, MD, PhD, Eun Ran Kim, MD, PhD, Dong Kyung Chang, MD, PhD, Young-Ho Kim, MD, PhD
doi : 10.1093/ibd/izad094
Volume 30, Issue 4, April 2024
Characterization of the Gut Microbiota and Mycobiota in Italian Pediatric Patients With Primary Sclerosing Cholangitis and Ulcerative ColitisÂ
Federica Del Chierico, MS, Sabrina Cardile, MD, Valerio Baldelli, PhD, Tommaso Alterio, MD, Sofia Reddel, MS, Matteo Bramuzzo, MD, Daniela Knafelz, MD, Sara Lega, MD, Fiammetta Bracci, MD, Giuliano Torre, MD, Giuseppe Maggiore, MD, PhD, Lorenza Putignani, PhD
doi : 10.1093/ibd/izad203
Impact of Inflammatory Bowel Disease on Patients’ Caregivers: Results From a French Survey
Weam El Hajj, MD, Anne Buisson, MD, Alain Olympie, MD, Marie Hélène Ravel, MD, Corinne Devos, MD, Caroline Trang-Poisson, MD, Gilles Macaigne, MD, Stéphane Nahon, MD
doi : 10.1093/ibd/izad093
Characteristics, Clinical Outcomes, and Prognosis of Anal and Pouch-related Carcinoma in Patients With Crohn’s Disease
Tanita Suttichaimongkol, MD, Edward V Loftus, Jr., MD
doi : 10.1093/ibd/izad104
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis
Sruthi Adimadhyam, PhD, James D Lewis, MD, MSCE, Andrew L Simon, ScM, Audrey E Wolfe, MPH, Samantha Smith, BA, Laura Hou, MS, Érick Moyneur, MA, Juliane S Reynolds, MPH, Sengwee Toh, ScD, Angela Dobes, MPH, Lauren Parlett, PhD, Kevin Haynes, PharmD, MSCE, Jessica Burris, MD, Jennifer E Dorand, PhD, Millie D Long, MD, MPH, Michael D Kappelman, MD, MPH
doi : 10.1093/ibd/izad115
Histological Disease Activity as Predictor of Clinical Relapse, Hospitalization, and Surgery in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Mohammad Shehab, MD, MRCP (United Kingdom), ABIM, FRCPC, Sahad Al Akram, MD, Amro Hassan, MD, Fatema Alrashed, MPharm, MSc, PharmD, BCPS, Vipul Jairath, MBChB, DPhil, Talat Bessissow, MDCM, MSc, FRCPC
doi : 10.1093/ibd/izad119
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-AnalysisÂ
Daniele Piovani, MSc, PhD, Alessandro Armuzzi, MD, PhD, Stefanos Bonovas, MD, MSc, PhD
doi : 10.1093/ibd/izad109
Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis
Vikas Taneja, MD, Rajsavi S Anand, MD, Mohammed El-Dallal, MD, Jeffrey Dong, MD, Nisa Desai, MD, Isha Taneja, MPH, Joseph D Feuerstein, MD
doi : 10.1093/ibd/izad108
Visceral Adiposity Independently Predicts Time to Flare in Inflammatory Bowel Disease but Body Mass Index Does Not
Priya Sehgal, MD, MPH, Steven Su, MD, PhD, John Zech, MD, Yael Nobel, MD, MS, Lyndon Luk, MD, Ioannis Economou, MD, Bo Shen, MD, James D Lewis, MD, Daniel E Freedberg, MD, MS
doi : 10.1093/ibd/izad111
Postvaccination Symptoms After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease: A Prospective, Comparative Study
Angela Mujukian, MD, Rashmi Kumar, MD, Dalin Li, PhD, Philip Debbas, Gregory J Botwin, Susan Cheng, MD, PhD, Joseph Ebinger, MD, Jonathan Braun, MD, PhD, Dermot McGovern, MD, PhD, Gil Y Melmed, MD, MS, The CORALE-IBD Study Group
doi : 10.1093/ibd/izad114
Revisiting the Role of Valeric Acid in Manipulating Ulcerative Colitis
Moting Liu, MSc, Yao Zhang, BSc, Jia Liu, PhD, Caigui Xiang, PhD, Qiukai Lu, MSc, Huimin Lu, PhD, Tao Yang, BSc, Xiaohan Wang, MSc, Qingli Zhang, MSc, Chen Fan, MSc, Chunlan Feng, BSc, Duowu Zou, PhD, MD, Heng Li, PhD, Wei Tang, PhD, MD
doi : 10.1093/ibd/izad187
Unveiling the Ghrelin and Obestatin Roles in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis Assessing Their Pathogenic Implications and Biomarker Utility
Amirmohammad Khalaji, MD, Nastaran Babajani, MD, Zahra Amirsardari, MD, Behrad Saeedian, MD, Soheil Peiman, MD, Nathan A Berger, MD, Amir Hossein Behnoush, MD, MPH
doi : 10.1093/ibd/izad202
Exclusive Enteral Nutrition Mediates Beneficial Gut Microbiome Enrichment in Acute Severe Colitis
Aditya Bajaj, MSc, Manasvini Markandey, MSc, Mukesh Singh, PhD, Pabitra Sahu, MD, DM, Sudheer K Vuyyuru, MD, DM, Bhaskar Kante, MD, DM, Peeyush Kumar, MD, DM, Mahak Verma, MSc, Govind Makharia, MD, DM, Saurabh Kedia, MD, DM, Simon P L Travis, DPhil, Vineet Ahuja, MD, DM
doi : 10.1093/ibd/izad232
Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis
Sudheer K Vuyyuru, MD, Tran M Nguyen, MSc, Malcolm Hogan, MSc, Tim Raine, MD, Nurulamin M Noor, MD, Neeraj Narula, MD, Bram Verstockt, MD, Brian G Feagan, MD, Siddharth Singh, MD, Christopher Ma, MD, Vipul Jairath, MBChB, Dphil
doi : 10.1093/ibd/izad052
Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel DiseaseÂ
Abhinav Vasudevan, MD, Vivek Tharayil, MD, Laura H Raffals, MD, David H Bruining, MD, Michelle Becker, PharmD, Mohammad Hassan Murad, MD, Edward V Loftus, Jr., MD
doi : 10.1093/ibd/izad065
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease
Nuria Tubau-Juni, PhD, Raquel Hontecillas, PhD, DVM, Andrew J Leber, PhD, Sameeksha S Alva, MS, Josep Bassaganya-Riera, PhD, DVM
doi : 10.1093/ibd/izad258
Use of Immune Checkpoint Inhibitors in Patients With Inflammatory Bowel Disease After Ileal Pouch-Anal Anastomosis
Christian Karime, MD, Francis A Farraye, MD, MSc, Jana G Hashash, MD, MSc
doi : 10.1093/ibd/izad098
Long-term Efficacy and Safety of Tacrolimus Plus Ustekinumab Combination Therapy in Children With Steroid-refractory Ulcerative ColitisÂ
Ryusuke Nambu, MD, Ayako Miyazawa, MD, Masashi Yoshida, MD, Tomoko Hara, MD, Itaru Iwama, MD
doi : 10.1093/ibd/izae013
Revisiting the Risk of Hospital Readmission in Severe Ulcerative Colitis
Yusuke Miyatani, MD, Dejan Micic, MD
doi : 10.1093/ibd/izad212
Surgical Complications Need to Be Carefully Excluded Before Ruling Out a Diagnosis of De Novo Crohn’s Disease
Massimo Martinelli, MD, PhD, Erasmo Miele, MD, PhD, Annamaria Staiano, MD
doi : 10.1093/ibd/izae026
Response to “De Novo Crohn’s Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN�
Djuna de Jong, MD, MSc, Maud Reijntjes, MD, PhD, Christianne Buskens, MD, PhD, Roel Hompes, MD, PhD, Geert D’Haens, MD, PhD, Willem Bemelman, MD, PhD, Marjolijn Duijvestein, MD, PhD
doi : 10.1093/ibd/izae021
Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance
Sem Geertsema, MD, Raphael R Fagundes, PhD, Antonius T Otten, MD, Gerard Dijkstra, MD, PhD, Klaas Nico Faber, PhD, Arno R Bourgonje, MD, PhD
doi : 10.1093/ibd/izae042
Reply: Interleukin-18 Inhibition in Inflammatory Bowel Diseases: A Delicate Balance
Keiko Maeda, MD, PhD, Hiroki Kawashima, MD, PhD
doi : 10.1093/ibd/izae039
